06/04/2026
CLL Society congratulates the Chair of our Medical Advisory Board, Dr. Matthew Davids on his appointment as Chief of the Division of Lymphoma, Dana-Farber Cancer Institute.
This recognizes Dr. Davids’ research in both the lab and the clinic in better understanding and treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) and other lymphomas.
While he will have increased administrative responsibilities, he remains dedicated to caring for patients with CLL, doing cutting edge research in his laboratory and through clinical trials, and in his role in guiding CLL Society’s Medical Advisory Board.
CLL patients are lucky to have physician/scientists like Dr. Davids exploring new ways to control our cancer.
This is from Dana Farber:
Matthew S. Davids, MD, MMSc, was recently appointed as Chief of the Division of Lymphoma, recognizing his longstanding leadership in clinical research, patient care, and innovation in blood cancer treatment.
"It is an honor to lead the Division of Lymphoma at Dana-Farber. I look forward to supporting our extraordinary team to better understand the biology underlying lymphoma, advance innovative therapies, and continue improving outcomes for patients with lymphoma and related diseases," said Davids.
Davids has been a member of our faculty since 2011 and most recently served as Director of Clinical Research in the Division of Lymphoma and Associate Director of the Center for Chronic Lymphocytic Leukemia (CLL). He is also an Associate Professor of Harvard Medical School.
Over the last 15 years, Davids has helped shape the institution's approach to lymphoma and CLL care through a combination of translational research and clinical leadership.
In his new role, Davids will oversee one of the nation's leading lymphoma programs, guiding clinical care, research strategy, and faculty development across the division. Please join us in congratulating him on this role.
